Embecta Corp. (NASDAQ:EMBC) Given Average Recommendation of “Reduce” by Brokerages

Shares of Embecta Corp. (NASDAQ:EMBC) have received an average recommendation of “Reduce” from the five brokerages that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation and three have issued a hold recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $11.00.

A number of analysts have issued reports on EMBC shares. Zacks Research raised Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Mizuho dropped their target price on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings downgraded shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday. Bank of America lowered their target price on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a report on Monday, May 18th. Finally, Wall Street Zen cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th.

Trending Headlines about Embecta

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates: Embecta reported adjusted EPS of $0.56, exceeding the $0.27 consensus estimate, while revenue of $271.7 million topped expectations of $254.5 million. Embecta Q3 earnings report
• Positive Sentiment: Full-year EPS outlook raised: Management provided fiscal 2026 EPS guidance of $1.80–$1.90, above the $1.60 analyst consensus, signaling stronger expected profitability despite business pressures. Embecta fiscal 2026 results
• Positive Sentiment: Dividend maintained: Embecta declared a quarterly cash dividend of $0.01 per share, providing a modest continuing shareholder return. Embecta dividend announcement
• Neutral Sentiment: Strategic diversification: Embecta reiterated its plan to expand beyond insulin delivery into a broader medical-supplies business. The strategy could create longer-term growth opportunities, but the release provided limited detail on execution or near-term returns. Embecta company announcement
• Negative Sentiment: Sales remain under pressure: Quarterly revenue fell 8.1% year over year to $271.7 million, and EPS declined from $1.12 in the comparable period. This highlights ongoing weakness in Embecta’s core operations even with the earnings beat. Embecta earnings details
• Negative Sentiment: Securities-fraud lawsuit adds risk: Multiple law firms publicized a class action alleging Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business. The August 17 lead-plaintiff deadline increases visibility around potential legal costs, damages and reputational risk. Embecta securities-fraud lawsuit notice

Embecta Stock Up 26.3%

Embecta stock opened at $4.42 on Friday. Embecta has a 52-week low of $2.77 and a 52-week high of $15.55. The firm has a market capitalization of $262.24 million, a price-to-earnings ratio of 2.33 and a beta of 0.81. The company has a fifty day simple moving average of $3.34 and a 200-day simple moving average of $6.66.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings results on Friday, August 7th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.27 by $0.29. The business had revenue of $271.70 million for the quarter, compared to analyst estimates of $254.53 million. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The company’s quarterly revenue was down 8.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, research analysts anticipate that Embecta will post 1.62 EPS for the current fiscal year.

Embecta Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th will be issued a $0.01 dividend. The ex-dividend date of this dividend is Thursday, August 27th. This represents a $0.04 dividend on an annualized basis and a yield of 0.9%. Embecta’s dividend payout ratio (DPR) is 2.11%.

Institutional Investors Weigh In On Embecta

A number of large investors have recently added to or reduced their stakes in EMBC. One Wealth Advisors LLC acquired a new position in shares of Embecta in the second quarter valued at approximately $33,000. Bank of America Corp DE lifted its stake in shares of Embecta by 45.7% during the 1st quarter. Bank of America Corp DE now owns 374,416 shares of the company’s stock worth $3,310,000 after purchasing an additional 117,448 shares during the period. Amundi lifted its holdings in shares of Embecta by 123.3% during the 1st quarter. Amundi now owns 23,798 shares of the company’s stock worth $210,000 after acquiring an additional 13,139 shares during the period. Parvin Asset Management LLC boosted its position in shares of Embecta by 11,010.9% in the first quarter. Parvin Asset Management LLC now owns 20,333 shares of the company’s stock worth $180,000 after acquiring an additional 20,150 shares during the last quarter. Finally, Saba Capital Management L.P. boosted its position in shares of Embecta by 10.3% in the first quarter. Saba Capital Management L.P. now owns 384,609 shares of the company’s stock worth $3,400,000 after acquiring an additional 36,000 shares during the last quarter. 93.83% of the stock is owned by institutional investors and hedge funds.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.